Cohance Lifesciences Limited — Investor Meet, 18-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Suven Pharmaceuticals witnessed robust growth in Q3 FY'25, reporting a 40% year-on-year revenue increase, marking a significant turnaround driven by heightened demand across its business units. For the nine months, the revenue grew by 5% year-on-year. The adjusted EBITDA margin stood at an impressive 38.7% for Q3 and 34.8% for the nine-month period. The pharma CDMO segment led the charge, growing 101% year-on-year in Q3 and 11% for the first nine months.

2. Future Outlook and Growth Drivers: Management foresees continued acceleration in growth, aiming to leverage its recent strategic acquisitions of Sapala and NJ Bio to enhance its capabilities in specialized pharmaceutical segments like antibody-drug conjugates and oligonucleotides. The company remains committed to its long-term goal of achieving USD 1 billion in revenue by FY'30, with expectations for significant traction beginning in FY'26.

3. Order Book and Operational Updates: The order book remains strong, with a doubling of RFQs compared to the previous year, reflecting confidence in Suven's capabilities. The addition of molecules into the Phase-3 pipeline demonstrates the company’s capacity for innovation and expansion.

4. Analyst Q&A Insights (Detailed):

- **Revenue and Profitability:** Management clarified that while growth from recently advanced molecules has yet to materialize fully, future demand is anticipated as partners ramp up activities.

- **Market Position and Competitive Landscape:** Analysts noted that Suven's participation in high-profile conferences enhanced visibility and fostered positive engagements with potential clients in the US, indicating a competitive advantage in the market.

- **Operational Challenges or Risks:** Management expressed confidence in managing supply chain risks, highlighting that they do not currently face capacity constraints despite past cyclical challenges.

- **Capex and Capital Allocation:** Suven’s capex for the nine-month period totaled ₹230 crore, primarily focused on capacity expansion and R&D scaling to align with market demand.

- **Strategic Priorities and Long-Term Vision:** The company's acquisitions are expected to synergize across CDMO platforms, bolstering growth in niche markets, notably oligonucleotides and ADCs.

5. Market or Regulatory Updates: The upcoming NCLT meeting for the Cohance merger is anticipated to provide a fresher perspective on growth projections. Successful completion of this merger could unlock new opportunities.

6. Strategic Focus Areas: A clear emphasis on innovation, operational efficiency, and expanding presence in the US and European markets indicates a strategic pivot towards addressing advanced pharmaceutical needs, potentially enhancing competitive positioning.

7. Investor Insight: Given the strong financial results alongside strategic growth drivers and a solid outlook, Suven Pharmaceuticals appears to be in a favorable position to capitalize on market opportunities. This aligns with a ‘buy’ stance, recognizing both existing strengths and future potential amidst operational expansion efforts.